Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Device aims to keep donor livers healthier for transplant

NCT ID NCT05082077

Disease control Sponsor: Paragonix Technologies Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are collecting data on how well donor livers preserved with the LIVERguard device function after transplantation. The study includes liver transplant recipients whose donor organs were stored in the device, as well as a comparison group of patients who received livers preserved using standard cold storage. The goal is to see whether the device affects outcomes such as organ survival, rejection, and hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LIVERguard, a device that keeps donor livers cold during transport
What this could lead to
If the device preserves livers well, it could help more donated organs reach patients in good condition and improve transplant outcomes.
What could go wrong
This is an observational registry, not a randomized trial, so it cannot prove cause and effect. Results may be influenced by differences in patients and centers, and the device may not outperform standard cold storage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have received a liver transplant at centers that use the LIVERguard device

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Donor and donor liver matched to the recipient based upon institutional medical practice * Registered male or female liver transplant candidates Exclusion Criteria: * Donor and donor liver that do not meet institutional clinical requirements for transplantation * Living donors

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver diseases Liver dysfunction Liver transplant disorder Liver transplant rejection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University

    Durham, North Carolina, 27710, United States

  • Intermountain Health Center

    Salt Lake City, Utah, 84111, United States

  • Lahey Clinic

    Burlington, Massachusetts, 01805, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Piedmont Healthcare

    Atlanta, Georgia, 30309, United States

  • Stanford University

    Stanford, California, 94305, United States

  • Tampa General Hospital

    Tampa, Florida, 33606, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35233, United States

  • University of California San Diego

    San Diego, California, 92093-0990, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45221, United States

  • University of Florida

    Gainesville, Florida, 32608, United States

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

  • University of Nebraska

    Omaha, Nebraska, 68198, United States

  • University of Texas Health Science Center at San Antonio

    San Antonio, Texas, 78229-3901, United States

  • University of Washington

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.